Bortezomib in multiple myeloma: Systematic review and clinical considerations

Current Oncology

Volumn 21, Issue 4, 2014, Pages

  Kouroukis, T C ^a   Baldassarre, Fulvia G ^b   Haynes, A E ^b   Imrie, K ^c   Reece, D E ^d   Cheung, M C ^c  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bortezomib; Multiple myeloma; Proteasome inhibitors; Systematic review

Indexed keywords

EID: 84905686235     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1798     Document Type: Review

References (94)

1. Yang H, Zonder JA, Dou QP. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 2009;18:957-71.
2. Health Canada. Approval of Velcade with conditions [letter to health professionals]. Ottawa, ON: Health Canada; 2006. [Available online at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/velcade_dhcpl_lapds_2006_098077-eng.pdf; cited January 5, 2011]
3. Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010;51:1424-43.
4. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Ver. 1.2011. Fort Washington, PA: nccn; 2011. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (free registration required); cited January 5, 2011]
5. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009;23:1716-30.
6. Reece D, Imrie K, Stevens A, Smith CA on behalf of the Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Curr Oncol 2006;13:162-72.
7. Barosi G, Merlini G, Billio A, et al. sie, sies, gitmo evidencebased guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Ann Hematol 2012;91:875-88.
8. Bird JM, Owen RG, D'Sa S, et al. on behalf of the Haematooncology Task Force of British Committee for Standards in Haematology (bcsh) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32-75.
9. Doss S, Hay N, Sutcliffe F. nice guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma. Lancet Oncol 2011;12:837-8.
10. Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol 2011;86:18-24.
11. Picot J, Cooper K, Bryant J, Clegg AJ. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-204.
12. Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010;84:379-90.
13. Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? Acta Haematol 2011;126:163-8.
14. Wang L, Ran X, Wang B, Sheng Z, Liu L. Novel agents-based regimens as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Hematol Oncol 2012;30:57-61.
15. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85.
16. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the ifm 2005-01 phase iii trial. J Clin Oncol 2010;28:4621-9.
17. Lonial S, Kaufman J, Tighiouart M, et al. A phase i/ii trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedulefinding study. Clin Cancer Res 2010;16:5079-86.
18. Ludwig H, Viterbo L, Greil R, et al. Bortezomib, thalidomide, and dexamethasone (vtd) versus vtd plus cyclophosphamide as induction therapy in previously untreated multiple myeloma patients eligible for hdt-asct: a randomized phase 2 trial [abstract 2312]. Blood 2009;114.
19. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41.
20. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase iii study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901.
21. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan- prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101-9.
22. Reece DE, Sullivan D, Lonial S, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011;67:57-67.
23. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
24. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
25. Hjorth M, Hjertner O, Knudsen LM, et al. on behalf of the Nordic Myeloma Study Group (nmsg). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 2012;88:485-96.
26. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (evolution) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82.
27. Sharma M, Khan H, Thall PF, et al. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012;118:2507-15.
28. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-8,5982.
29. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study. Lancet Oncol 2011;12:431-40. [Erratum in: Lancet Oncol 2011;12:522]
30. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The mmvar/ifm 2005-04 randomized phase iii trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:2475-82.
31. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase iii hovon-65/gmmg-hd4 trial. J Clin Oncol 2012;30:2946-55.
32. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007;137:429-35.
33. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the apex trial. Blood 2007;110:3557-60.
34. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the apex phase 3 study. Leukemia 2008;22:842-9.
35. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase iii apex study. J Clin Oncol 2008;26:4784-90.
36. Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the apex study. Br J Haematol 2008;143:511-19.
37. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 apex trial in relapsed multiple myeloma. Br J Haematol 2008;143:46-53.
38. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase iii apex trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144:895-903.
39. Vogl DT, Stadtmauer EA, Richardson PG, et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol 2009;147:531-4.
40. San Miguel JF, Richardson PG, Orlowski RZ, et al. Risk of second primary malignancies (spms) following bortezomib (Btz)-based therapy: analysis of four phase 3 randomized controlled trials in previously untreated or relapsed multiple myeloma (mm) [abstract 2933]. Blood 2011;118.
41. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. 2008;112:1529-37.
42. Shah J, Blade J, Sonneveld P, et al. The effect of paraprotein heavy chain and free light chain types on the efficacy of pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in patients with relapsed/refractory multiple myeloma [abstract 5190]. Blood 2008;112.
43. Shah J, Blade J, San Miguel J, et al. The effect of bone marrow involvement on the efficacy of pegylated liposomal doxorubicin + bortezomib vs. bortezomib alone in patients with relapsed/refractory multiple myeloma [abstract 5192]. Blood 2008;112.
44. Buda G, Ricci D, Cohen N, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with relapsed and/or refractory multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin [abstract 109]. Blood 2009;114.
45. San Miguel JF, Schlag R, Khuageva NK, et al. Updated follow-up and results of subsequent therapy in the phase III vista trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma [abstract 650]. Blood 2008;112.
46. Harousseau JL, Palumbo A, Richardson P, et al. Superior outcomes associated with complete response: analysis of the phase III vista study of bortezomib plus melphalan-prednisone versus melphalan-prednisone [abstract 2778]. Blood 2008;112.
47. Dhawan R, Robinson D Jr, Meunier J, et al. Sustained healthrelated quality of life (HRQOL) improvement in newly diagnosed multiple myeloma patients treated with bortezomib/melphalan/prednisone versus melphalan/prednisone: results from the vista trial [abstract 1881]. Blood 2009;114.
48. Dimopoulos MA, Richardson PG, Schlag R, et al. vmp (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III vista study. J Clin Oncol 2009;27:6086-93.
49. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III vista trial. J Clin Oncol 2010;28:2259-66.
50. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 vista study. Eur J Haematol 2011;86:23-31.
51. Favis R, Sun Y, van de Velde H, et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 2011;21:121-9.
52. Delforge M, Terpos E, Richardson PG, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III vista trial in multiple myeloma. Eur J Haematol 2011;86:372-84.
53. San Miguel JF, Schlag R, Khuageva NK, et al. Continued overall survival benefit after 5 years' follow-up with bortezomib- melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 vista trial [abstract 476]. Blood 2011;118.
54. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-53.
55. Avet-Loiseau H, Moreau P, Mathiot C, et al. Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma [abstract 8113]. J Clin Oncol 2010;28. [Available online at: http://meetinglibrary.asco.org/content/48562-74; cited April 14, 2014]
56. Moreau P, Hulin C, Marit G, et al. on behalf of the ifm group. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to ifm 2005-01 trial. Leukemia 2010;24:1233-5.
57. Moreau P, Attal M, Pegourie B, et al. Achievement of vgpr to induction therapy is an important prognostic factor for longer pfs in the ifm 2005-01 trial. Blood 2011;117:3041-4.
58. Cavo M, Tacchetti P, Patriarca F, et al. A phase iii study of double autotransplantation incorporating bortezomib-thalidomide- dexamethasone (vtd) or thalidomide-dexamethasone (td) for multiple myeloma: superior clinical outcomes with vtd compared to td (abstract 351). Blood 2009;114.
59. Brioli A, Perrone G, Volpe S, et al. Autologous peripheral blood stem-cell (pbsc) collection is not impaired by bortezomib- thalidomide-dexamethasone (btd) induction therapy in newly diagnosed multiple myeloma (mm) [abstract 317]. Blood 2011;118.
60. Cavo M, Pantani L, Patriarca F, et al. Superior complete response rate (cr) and progression-free survival (pfs) with bortezomib-thalidomide-dexamethasone (vtd) versus thalidomide-dexamethasone (td) as consolidation therapy after autologous stem-cell transplantation (asct) in multiple myeloma (mm) [abstract 1871]. Blood 2011;118.
61. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9-19.
62. Tacchetti P, Terragna C, Catania G, et al. Bortezomib- and thalidomide-induced peripheral neuropathy (pn) in multiple myeloma (mm): clinical and molecular analysis of 474 patients treated with thalidomide-dexamethasone (td) or bortezomibtd (vtd) [abstract 1821]. Blood 2011;118.
63. Sharma M, Thall P, Wang X, et al. A randomized phase ii trial of high-dose melphalan, ascorbic acid and arsenic trioxide with or without bortezomib in multiple myeloma [abstract 2309]. Blood 2009;114.
64. Mateos MV, Oriol A, Teruel AI, et al. Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the gem2005mas65 Spanish randomized trial [abstract 477]. Blood 2011;118.
65. Kumar S, Flinn IW, Hari PN, et al. Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi-center, randomized, phase 2 evolution study [abstract 127]. Blood 2009;114.
66. Kumar A, Flinn I, Richardson P, et al. Final results from the multi-center, randomized, phase 2 evolution study of combinations of bortezomib (v), dexamethasone (d), clophosphamide (c), and lenalidomide (r) in previously untreated multiple myeloma (mm) [abstract S100]. Haematologica 2011;96.
67. Kumar A, Kimlinger T, Morice WG, et al. Minimal residual disease (mrd) assessment by multiparameter flow cytometry (fcm) in a multicenter randomized phase 2 study in newly diagnosed multiple myeloma (mm): feasibility and correlation with response and survival outcomes [abstract S99]. Haematologica 2011;96.
68. Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: effects of subcutaneous injection site and concentration, and patient characteristics [abstract 1863]. Blood 2011;118.
69. Moreau P, Facon T, Attal M, et al. Comparison of reduceddose bortezomib plus thalidomide plus dexamethasone (vtd) to bortezomib plus dexamethasone (vd) as induction treatment prior to asct in de novo multiple myeloma (mm): results of ifm 2007-02 study [abstract 8014]. J Clin Oncol 2010;28. [Available online at: http://meetinglibrary.asco.org/content/43424-74; cited April 14, 2014]
70. Sonneveld P, van der Holt B, SchmidtWolf IGH, et al. First analysis of hovon-65/gmmg-hd4 randomized phase iii trial comparing bortezomib, Adriamycine, dexamethasone (PAD) vs. vad as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract 653]. Blood 2008;112.
71. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940-8.
72. Mellqvist UH, Gimsing P, Hjertner O, et al. Improved progression free survival with bortezomib consolidation after high dose melphalan; results of a randomized phase iii trial [abstract S31]. Haematologica 2011;96.
73. Rosinol L, Cibeira MT, Martinez J, et al. Thalidomide/dexamethasone (td) vs. bortezomib (Velcade)/thalidomide/dexamethasone (VTD) vs. vbmcp/vbad/Velcade as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase iii pethema/gem trial [abstract 130]. Blood 2009;114.
74. Rosinol L, Cibeira MT, Mateos MV, et al. A phase iii pethema/gem randomized trial of postransplant (asct) maintenance in multiple myeloma: superiority of bortezomib/thalidomide compared with thalidomide and alfa-2b interferon [abstract 3962]. Blood 2011;118.
75. Niesvizky R, Reeves J, Flinn IW, et al. Phase 3b upfront study: interim results from a community practice-based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients [abstract 129]. Blood 2009;114.
76. Niesvizky R, Flinn IW, Rifkin R, et al. Patient-reported quality of life (qol) in elderly, newly diagnosed multiple myeloma (mm) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b upfront study [abstract 1864]. Blood 2011;118.
77. San-Miguel JF, De Moraes Hungria VT, Yoon SS, et al. Update on a phase iii study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: panorama 1 [abstract 3976]. Blood 2011;118.
78. Kaura S, Dranitsaris G. Number needed to treat (nnt) as a measure of drug benefit: lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (mm) [abstract e18562]. J Clin Oncol 2012;30. [Available online at: http://meetinglibrary.asco.org/content/96962-114; cited April 14, 2014]
79. Mellqvist UH, Westin J, Gimsing P, et al. Improved response rate with bortezomib consolidation after high dose melphalan: first results of a Nordic Myeloma Study Group randomized phase iii trial [abstract 530]. Blood 2009;114.
80. Dimopoulos MA, Jagannath S, Yoon SS, et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial [abstract 811]. Blood 2011;118.
81. Dimopoulos MA, Beksac M, Benboubker L, et al. Bortezomib- dexamethasone alone or plus cyclophosphamide or lenalidomide as second-line treatment for patients with multiple myeloma: final results from a phase 2 study [abstract 1861]. Blood 2011;118.
82. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b upfront study [abstract 478]. Blood 2011;118.
83. Orlowski RZ, Gercheva L, Williams C, et al. Phase ii, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma [abstract 8018]. J Clin Oncol 2012;30:8018. [Available online at: http://meetinglibrary.asco.org/content/96732-114; cited April 4, 2014]
84. Rosinol L, Cibeira MT, Mateos MV, et al. A phase iii pethema/gem randomised trial of posttransplant maintenance in multiple myeloma: superiority of bortezomib. Bone Marrow Transplant 2012;47:S2.
85. San Miguel JF, Moreau P, Yoon SS, et al. Phase iii study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (panorama 1) [abstract 18572]. J Clin Oncol 2012;30. [Available online at: http://meetinglibrary.asco.org/content/91326-114; cited April 14, 2014]
86. Shea BJ, Hamel C, Wells GA, et al. amstar is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013-20.
87. Shea BJ, Grimshaw JM, Wells GA, et al. Development of amstar: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
88. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (fact/gog-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741-8.
89. Fayers PM, Aaronson N, Bjordal K, Curran D, Groenvold M. The EORTC QLQ-C30 Scoring Manual. 2nd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 1999.
90. Calhoun EA, Fishman DA, Roland PY, Lurain JR, Chang C, Cella D. Validity and selective sensitivity of the fact-gog Ntx [abstract 446a]. J Clin Oncol 2000;19.
91. Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008;34:442-52.
92. Hicks LK, Haynes AE, Reece D, et al. on behalf of the Hematology Disease Site Group. Thalidomide in Multiple Myeloma: Guideline Recommendations. Evidence-based series 6-21. Section 1. Toronto, ON: Cancer Care Ontario; 2010.
93. Nooka AK, Kaufman JL, Behera M, et al. The improved efficacy of bortezomib containing induction regimens (bcir) versus non-bortezomib containing induction regimens (nbcir) in transplant-eligible patients with multiple myeloma (mm): meta-analysis of phase iii randomized controlled trials (rcts) [abstract 3994]. Blood 2011;118.
94. Kouroukis CT, Fernandez LAV, Crump M, et al. A phase ii study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (ind 172). Leuk Lymphoma 2011;52:394-9. [Erratum in: Leuk Lymphoma 2011;52:1160]